Nymox Pharmaceutical Corp
NYMXF- Exchange
- OTC
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001018735
No open-market purchases or sales by Nymox Pharmaceutical Corp insiders were filed in the last 90 days; 1 institution reported holding it in 13F filings for Q2 2026, worth $4.21K in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Nymox Pharmaceutical Corp insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Nymox Pharmaceutical Corp, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Robinson James George | Director, 10% Owner | 4,782,065 | Jun 26, 2023 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2023 (view filing)10:27 AM ET | Apr 25-27 | 62 days | Robinson James GeorgeDirector, 10% Owner | PPurchase | +80.0K | $0.46 | +$36.8K | +1.7%4.78M after | Amended2 lots |
| May 6, 2022 (view filing) | May 2 | 4 daysLate | Robinson James GeorgeDirector | PPurchase | +1.15M | $1.65 | +$1.90M | +32.4%4.70M after | |
| May 6, 2022 (view filing) | May 2 | 4 daysLate | Robinson James GeorgeDirector | PPurchase | +1.15M | $0.00 | $0 | –1.15M after | Derivative |